Form 4: Revolution Medicines COO Executes Stock Option Exercises
Statement of Changes in Beneficial Ownership
Chief Operating Officer Margaret Horn exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- COO Margaret Horn exercised options for 90,000 shares of common stock across multiple dates in June 2026.
- The exercise prices for these options ranged from $26.50 to $40.74 per share.
- Following the exercises, the reporting person sold 90,000 shares at weighted average prices between $156.12 and $160.17.
- The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive equity management.
Positives
- The executive maintains a significant remaining equity stake of 154,647 shares.
- Transactions were executed under a pre-established 10b5-1 plan, indicating systematic rather than reactive selling.
Negatives
- The executive reduced their direct beneficial ownership through the sale of 90,000 shares.
Risks
- Future share price volatility could impact the value of remaining unvested equity holdings.
- Continued reliance on 10b5-1 plans for liquidity may signal ongoing divestment by key management.
Future Outlook
No specific forward-looking guidance regarding company operations was provided; the filing is strictly a disclosure of insider equity transactions.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for biotech executives to manage tax obligations and diversify personal portfolios, and does not necessarily reflect a change in management's outlook on the company's clinical pipeline.
Comparison to Industry Standards
- The use of 10b5-1 plans is a standard governance practice among S&P 500 and NASDAQ-listed biotech firms to avoid allegations of insider trading.
- The scale of the sale is consistent with typical executive compensation liquidity events in the mid-cap biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | Reporting person adopted a 10b5-1 trading plan on March 12, 2026. | 03/12/2026 | Provides a legal affirmative defense for scheduled equity transactions. |
Stakeholder Impact
- Shareholders should view this as a routine liquidity event for the COO rather than a signal of operational distress.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/16/2025 | Date of a specific share sale transaction related to tax withholding. |
| 06/15/2026 | Earliest transaction date for the primary option exercises and sales. |
| 06/17/2026 | Final transaction date for the reported option exercises and sales. |
Keywords
Revolution Medicines, RVMD, Insider Trading, Form 4, Biotech, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.